Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II SPP-003 for cisplatin-induced nephrotoxicity in lung cancer
jRCT2080224098Phase 2Completed
- Sponsor
- SBI Pharmaceuticals
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchial carcinoma and Cisplatin-Induced Nephropathy comparing SPP-003 arm with Placebo arm (2 arms). Started Oct 2018; status: completed.
02
Drugs
5-aminolevulinic acid hydrochloride + sodium ferrous citrate
03
Conditions
bronchial carcinomaCisplatin-Induced Nephropathy
Beyond the preview
Go deeper on jRCT2080224098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224098.